RecruitingPhase 2NCT03128879

Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL

A Phase II Study of Venetoclax (ABT-199) Consolidation for Patients Currently Receiving Ibrutinib or Acalabrutinib for High-risk CLL

Sponsor

M.D. Anderson Cancer Center

Enrollment

90 participants

Start Date

Jun 16, 2017

Study Type

INTERVENTIONAL

Conditions

Chronic Lymphocytic Leukemia

Summary

This is a single center, open-label, phase II study of venetoclax (ABT-199) added to ibrutinib or acalabrutinib in patients with high-risk CLL who have received at least 12 months of ibrutinib or acalabrutinib monotherapy. The study will estimate the therapeutic efficacy of venetoclax consolidation in patients who have detectable CLL after receiving ibrutinib or acalabrutinib for at least 12 months and who have high risk CLL.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This trial is testing a combination of three drugs — venetoclax, and ibrutinib or acalabrutinib — for people with a high-risk form of chronic lymphocytic leukemia (CLL), a type of blood cancer. **You may be eligible if...** - You have been diagnosed with CLL or small lymphocytic lymphoma (SLL) - Your cancer has certain high-risk genetic features, such as a deletion of chromosome 17p, a mutation in the TP53 gene, or a complex chromosome pattern - You may also qualify if these genetic abnormalities were present before you started ibrutinib or acalabrutinib therapy **You may NOT be eligible if...** - Your CLL does not have these specific high-risk genetic markers - You have other serious health conditions that make these drugs unsafe for you Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.